Showing papers by "Julie M. Vose published in 2004"
National Institutes of Health1, University of Würzburg2, University of British Columbia3, University of Nebraska Medical Center4, University of Rochester5, Oregon Health & Science University6, University of Arizona7, Fred Hutchinson Cancer Research Center8, University of Oslo9, St Bartholomew's Hospital10, University of Barcelona11
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
Abstract: background Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival. methods Gene-expression profiling was performed on 191 biopsy specimens obtained from patients with untreated follicular lymphoma. Supervised methods were used to discover expression patterns associated with the length of survival in a training set of 95 specimens. A molecular predictor of survival was constructed from these genes and validated in an independent test set of 96 specimens. results Individual genes that predicted the length of survival were grouped into gene-expression signatures on the basis of their expression in the training set, and two such signatures were used to construct a survival predictor. The two signatures allowed patients with specimens in the test set to be divided into four quartiles with widely disparate median lengths of survival (13.6, 11.1, 10.8, and 3.9 years), independently of clinical prognostic variables. Flow cytometry showed that these signatures reflected gene expression by nonmalignant tumor-infiltrating immune cells. conclusions The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
1,336 citations
TL;DR: Interestingly, the t(14;18)-negative subset is dominated by overexpression of cell cycle-associated genes, indicating that these tumors are significantly more proliferative, suggesting distinctive pathogenetic mechanisms.
Abstract: Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed prognostically important subgroups: germinal center B-cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, and primary mediastinal large B-cell lymphoma. The t(14;18)(q32;q21) has been reported previously to define a unique subset within the GCB-DLBCL. We evaluated for the translocation in 141 cases of DLBCL that were successfully gene expression profiled. Using a dual-probe fluorescence in situ hybridization assay, we detected the t(14;18) in 17% of DLBCLs and in 34% of the GCB subgroup which contained the vast majority of positive cases. In addition, 12 t(14;18)-positive cases detected by polymerase chain reaction assays on additional samples were added to the fluorescence in situ hybridization-positive cases for subsequent analysis. Immunohistochemical data indicated that BCL2, BCL6, and CD10 protein were preferentially expressed in the t(14;18)-positive cases as compared to t(14;18)-negative cases. Within the GCB subgroup, the expression of BCL2 and CD10, but not BCL6, differed significantly between cases with or without the t(14;18): 88% versus 24% for BCL2 and 72% versus 32% for CD10, respectively. In the GCB-DLBCL subgroup, a heterogeneous group of genes is overexpressed in the t(14;18)-positive subset, among which BCL2 is a significant discriminator. Interestingly, the t(14;18)-negative subset is dominated by overexpression of cell cycle-associated genes, indicating that these tumors are significantly more proliferative, suggesting distinctive pathogenetic mechanisms. However, despite this higher proliferative activity, there was no significant difference in overall or failure-free survival between the t(14;18)-positive and -negative subsets within the GCB subgroup.
295 citations
TL;DR: B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy and a dose escalation trial of (90)Y-DOTA-biotin in this format is warranted.
141 citations
TL;DR: Allo-HSCT is feasible for patients with lymphoma who have relapses after autologous hematopoietic stem cell transplantation and can result in prolonged survival for some, but it is usually not curative.
100 citations
TL;DR: It is suggested that Bexxar will become an important new option in the treatment of indolent lymphomas, and the gamma emissions of iodine-131 facilitate accurate dosimetry to calculate the appropriate patient-specific therapeutic activity to deliver a predetermined total-body dose of radiation, thereby minimizing hematologic toxicity.
Abstract: Purpose. Immunotherapy using monoclonal antibodies to specifically target B cells has provided new hope to many patients with indolent lymphomas, particularly those with chemotherapy-refractory disease. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with anti-CD20 antibodies. Materials and Methods. Herein we review clinical experience with tositumomab and iodine I 131 tositumomab (Bexxar ® ; Corixa Corporation; South San Francisco, CA; and GlaxoSmithKline; Philadelphia, PA) in patients with non-Hodgkin’s lymphoma. Results. Therapy with Bexxar has demonstrated high response rates and long durations of response compared with unconjugated anti-CD20 antibodies in patients with relapsed low-grade and transformed low-grade non-Hodgkin’s lymphomas. Iodine-131 (I131) has a long history of clinical experience, an excellent safety record, and favorable nuclear and pharmacologic properties. Importantly, the gamma emissions of iodine-131 facilitate accurate dosimetry to calculate the appropriate patient-specific therapeutic activity to deliver a predetermined total-body dose of radiation, thereby minimizing hematologic toxicity. In clinical trials of Bexxar, objective response rates ranged from 54%-71% in heavily pretreated patients. In the pivotal trial, the number of patients with a longer duration of response after treatment with Bexxar was significantly greater than the number of patients with a longer duration of response after their last qualifying chemotherapy regimen. In 76 newly diagnosed patients, the objective response rate was 97%, and 63% of patients achieved complete responses. Conclusion. These data suggest that Bexxar will become an important new option in the treatment of indolent lymphoma. The Oncologist 2004;9:160-172
72 citations
TL;DR: Both pre-therapy and post-Therapy VEGF levels were independently predictive of survival in patients with HD, and post thetherapy levels of angiogenin were independently predicting of survival.
70 citations
62 citations
University of Nebraska Medical Center1, Medical College of Wisconsin2, University of California, San Diego3, University of Minnesota4, Memorial Hospital of South Bend5, Royal Prince Alfred Hospital6, University of Texas MD Anderson Cancer Center7, University of Louisville8, Roswell Park Cancer Institute9, Memorial Sloan Kettering Cancer Center10, University of Utah11, Millennium Pharmaceuticals12, University of Chicago13
TL;DR: In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age >or=40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival.
57 citations
TL;DR: Each phase in the development of acute GVhd is reviewed and recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways are discussed.
30 citations
TL;DR: The data continue to support the activity of bortezomib in pts.
16 citations
TL;DR: In the univariate analysis, significant adverse predictors for OS were age ≥60 years, B symptoms, elevated serum LDH, low hemoglobin, and high International Prognostic Index (IPI) score (3–5).
Abstract: The term "B-cell small lymphocytic lymphoma" (B-SLL) is generally reserved for patients with lymph node masses that show the histology and immunophenotype of B-cell chronic lymphocytic leukemia (B-CLL) but who are not leukemic. The aim of our study was to define clinical factors that predict for survival in B-SLL. Thirty-nine patients with B-SLL and with less than 5,000 mature-appearing lymphocytes/microL in the peripheral blood were studied. The median follow-up of survivors was 6.6 years (range, 1.6-12.3 years). The estimated 5-year overall survival (OS) and failure-free survival (FFS) were 66% and 23%, respectively. In the univariate analysis, significant adverse predictors for OS were age > or =60 years, B symptoms, elevated serum LDH, low hemoglobin (<11 g/dL), and high International Prognostic Index (IPI) score (3-5). In multivariate analysis, the IPI score was the only significant predictor of OS. Anemia and B symptoms were additionally predictive of poor OS in patients with low IPI scores.
TL;DR: While RR decreased with number of prior therapies, the durations of response and percent in continuous response after Bexxar were substantial and consistent across the range of the number ofPrior therapies.
TL;DR: Concerns of increased resistance of DLBCL following failure of CHOP-R and the inability to salvage those patients with high-dose chemotherapy and autologous stem cell transplantation have been raised.
Journal Article•
TL;DR: In this pivotal study of BEXXAR, durable remissions of ≥5 yrs were achieved following only 1 wk of therapy in 9 heavily pretreated patients with LG, follicular, or transformed NHL who had many poor prognostic features for their disease.
TL;DR: BEXXAR can be administered safely and effectively to older pts with low-grade follicular or transformed NHL treated with BexXAR, and response rates and durations of response are somewhat better in younger pts than in older pts, but pts >60 yrs presented with poorer prognostic features.
TL;DR: Primary mediastinal B cell lymphoma has been recognized as a subtype of diffuse large B Cell lymphoma (DLBCL) with distinct characteristics and seen most often in young people.
Abstract: 6585 Background: Primary mediastinal B cell lymphoma (PMBL) has been recognized as a subtype of diffuse large B cell lymphoma (DLBCL) with distinct characteristics (e.g.: seen most often in young f...
TL;DR: In this paper, the authors conducted a retrospective study to identify the outcome and clinical features predictive of survival in patients with grade 3 follicular lymphoma (FL3) using the Berard criteria, who were staged and treated with various aggressive combination chemotherapy regimens containing either an anthracycline or mitoxantrone.
TL;DR: The purpose of this study was to determine whether FDG-PET+CT result in a more accurate response classificati...
Abstract: 6533 Background: FDG-PET is increasingly being utilized for response assessment of NHL. The purpose of this study was to determine whether FDG-PET+CT result in a more accurate response classificati...